This clinical trial, sponsored by Hamilton Health Sciences Corporation, investigates the potential disease-modifying effects of doxycycline and rifampicin on Alzheimer's disease biomarkers. Given the increasing prevalence of Alzheimer's and the limited efficacy of current treatments, successful outcomes could position these antibiotics as novel therapeutic options, potentially capturing a significant share of the Alzheimer's treatment market. The trial's completion in 2010 suggests that data may be available for analysis, which could inform future development strategies and partnerships. However, the competitive landscape includes established therapies and ongoing research into disease-modifying agents, necessitating thorough diligence to assess market entry strategies and potential collaborations.